Tergus to Build Plant and Invest in Expanding Commercial Manufacturing

| By | CDMO, Drug Manufacturing

Tergus Pharma (“Tergus”), an end-to-end service provider for topical pharmaceutical research, drug development, testing and manufacturing, has announced a 100,000-square-foot building for its new headquarters and plans to invest to expand into commercial manufacturing. Tergus will provide comprehensive services from development through manufacturing and will become a Contract Development and Manufacturing Organization, or CDMO.

Tergus announced a partnership with Great Point Partners (“GPP”) a Greenwich, Connecticut based health care investment firm. GPP has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies.

Tergus provides Topical Formulation development, In Vitro Permeating Testing (IVPT), In Vitro Release Testing (IVRT), Skin Biology, Analytical services, and Clinical Trial Materials (CTM) manufacturing services for branded and generic dermatology products. Great Point’s investment will allow Tergus to build a state-of-the-art commercial manufacturing facility in the Raleigh-Durham, NC area and will begin construction in July 2019. The new 100,000 square foot facility will have Clinical Trial Material (Phases I through III) Supplies and commercial manufacturing capabilities and expand current capacity by over 400%. Tergus plans to open the new facility in early 2020.

Great Point’s expertise and successful track record growing pharmaceutical services companies was evident when they proactively approached us about a partnership. For years we have discussed building a commercial facility. The equity capital from GPP will enable us to do this and we will be able to better serve our customers by offering end-to-end services including commercial manufacturing. Great Point’s experience, network, and success in current and previous outsourced pharmaceutical services investments was a true differentiator,

said Vijendra Nalamothu, Ph.D., CEO of Tergus.

Tergus has differentiated itself as a leader in the complex topical dermatology development space that has been growing at ~15% per year. Tergus’ reputation within topical dermatology is unparalleled and we are thrilled that Tergus will now be a ‘one-stop-shop’ from clinical development to commercial manufacturing for all of their clients,

said Rohan Saikia,
Managing Director at Great Point Partners.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.